September 14, 2023

Lawstreet Media: Addimmune Goes Public in Bid to Cure HIV

law street

View the full Article on:
Law Street Media

Addimmune Summary

This article reports on Addimmune’s decision to go public, highlighting the transformative potential of our HIV gene therapy. As the HIV division of American Gene Technologies, we are committed to finding a breakthrough cure for a disease that affects millions globally.

Our transition to a publicly traded company positions us for accelerated growth and rapid advancement of this groundbreaking therapy. The increased funding and resources will be pivotal in supporting our ongoing clinical trials and bringing this innovative approach closer to reality.

At Addimmune, we believe our HIV gene therapy holds the key to a functional cure. The decision to go public reflects our unwavering commitment to revolutionizing HIV treatment and ultimately finding a cure.